keyword
MENU ▼
Read by QxMD icon Read
search

Cardiovascular Secondary prevention

keyword
https://www.readbyqxmd.com/read/29344794/ticagrelor-for-secondary-prevention-of-atherothrombotic-events-after-myocardial-infarction-an-evidence-review-group-perspective-of-a-nice-single-technology-appraisal
#1
REVIEW
Xavier G L V Pouwels, Robert Wolff, Bram L T Ramaekers, Anoukh Van Giessen, Shona Lang, Steve Ryder, Gill Worthy, Steven Duffy, Nigel Armstrong, Jos Kleijnen, Manuela A Joore
The National Institute for Health and Care Excellence (NICE) invited AstraZeneca, the manufacturer of ticagrelor (Brilique®), to submit evidence on the clinical and cost effectiveness of ticagrelor 60 mg twice daily (BID) in combination with low-dose aspirin [acetylsalicylic acid (ASA)] compared with ASA only for secondary prevention of atherothrombotic events in patients with a history of myocardial infarction (MI) and who are at increased risk of atherothrombotic events. Kleijnen Systematic Reviews Ltd (KSR), in collaboration with Maastricht University Medical Centre+, was commissioned as the evidence review group (ERG)...
January 18, 2018: PharmacoEconomics
https://www.readbyqxmd.com/read/29344384/blood-pressure-target-achievement-and-antihypertensive-medication-use-in-women-and-men-after-first-ever-myocardial-infarction-the-troms%C3%A3-study-1994-2016
#2
Laila A Hopstock, Anne Elise Eggen, Maja-Lisa Løchen, Ellisiv B Mathiesen, Amalie Nilsen, Inger Njølstad, Tom Wilsgaard
Background: Recurrent cardiovascular events after myocardial infarction (MI) are frequent, and gender differences in blood pressure treatment have been reported. Despite increased focus on secondary prevention, recent reports indicate that treatment targets are not achieved. There is a need for gender-specific analyses of post-MI blood pressure treatment target achievement and antihypertensive medication adherence. Design: We investigated the change in systolic and diastolic blood pressure and antihypertensive drug use after first-ever MI over two time periods in a Norwegian population-based study...
2018: Open Heart
https://www.readbyqxmd.com/read/29344376/effectiveness-of-pharmacist-s-intervention-in-the-management-of-cardiovascular-diseases
#3
REVIEW
Stefano Omboni, Marina Caserini
The pharmacist may play a relevant role in primary and secondary prevention of cardiovascular diseases, mainly through patient education and counselling, drug safety management, medication review, monitoring and reconciliation, detection and control of specific cardiovascular risk factors (eg, blood pressure, blood glucose, serum lipids) and clinical outcomes. Systematic reviews of randomised controlled and observational studies have documented an improved control of hypertension, dyslipidaemia or diabetes, smoking cessation and reduced hospitalisation in patients with heart failure, following a pharmacist's intervention...
2018: Open Heart
https://www.readbyqxmd.com/read/29339691/rationale-design-and-methodology-of-the-evaluation-of-perceptions-knowledge-and-compliance-with-the-guidelines-in-real-life-practice-a-survey-on-the-under-treatment-of-hypercholesterolemia
#4
Volkan Doğan, Özcan Başaran, Bülent Özlek, Oğuzhan Çelik, Eda Özlek, Kadir Uğur Mert, İbrahim Rencüzoğulları, Gurbet Özge Mert, Marwa Mouline Doğan, Murat Biteker, Meral Kayıkçıoğlu
OBJECTIVE: A wide gap exists between dyslipidemia guidelines and their implementation in the real world, which is primarily attributed to physician and patient compliance. The aim of this study is to determine physician and patient adherence to dyslipidemia guidelines and various influential factors. METHODS: The Evaluation of Perceptions, Knowledge, and Compliance with the Guidelines in Real Life Practice: A Survey on the Under-treatment of Hypercholesterolemia (EPHESUS) trial (ClinicalTrials...
January 2018: Türk Kardiyoloji Derneği Arşivi: Türk Kardiyoloji Derneğinin Yayın Organıdır
https://www.readbyqxmd.com/read/29337458/-pulmonary-diseases-asthma-copd-and-sleep-apnea-syndrome
#5
Béatrice Duxbury, Émilie Chappuis-Gisin, Salim Chucri, Jean-Paul Janssens
Among the novelties described in the management of pulmonary disorders during the year 2017, we chose to describe three. First, the indication for inhaled glucocorticosteroids (ICS) in COPD has been revisited, because of their relationship with an increased occurence of pneumonia : ICS are now recommended only in severe COPD (GOLD D) with frequent exacerbations as second line treatment. Secondly, azithromycine has shown very promising results in poorly controlled severe asthma, with a significant impact on symptoms and exacerbations...
January 10, 2018: Revue Médicale Suisse
https://www.readbyqxmd.com/read/29326775/a-systematic-review-on-the-prevalence-of-acute-myocardial-infarction-in-iran
#6
REVIEW
Jaber Mohseni, Toba Kazemi, Mahmood Hosseinzadeh Maleki, Hossein Beydokhti
In Iran, cardiovascular diseases are the most common causes of death. We aimed to perform a systematic review on the prevalence of acute myocardial infarction (AMI) in Iran based on Persian and English papers had been published from 1985 to 2015. Among 267 initially found articles, 142 were excluded; finally, a total number of 40 articles were found relevant which were reduced to 18. Smoking, hypertension, diabetes mellitus, and hypercholesterolemia were the most common risk factors for AMI. Premature MI prevalence was high in men, and smoking was the most common risk factor among young people...
October 2017: Heart Views: the Official Journal of the Gulf Heart Association
https://www.readbyqxmd.com/read/29325803/coronary-artery-disease-in-athletes-an-adverse-effect-of-intense-exercise
#7
REVIEW
Hélder Dores, Pedro de Araújo Gonçalves, Nuno Cardim, Nuno Neuparth
Regular physical exercise is responsible for various health benefits, and is recommended for primary and secondary cardiovascular (CV) prevention. Despite these recognized benefits, various clinical events can occur in athletes, including acute myocardial infarction and sudden cardiac death (SCD); the main cause of SCD in veteran athletes is coronary artery disease (CAD). The relationship between intense exercise training and CAD is controversial, and a U-shaped association has been hypothesized. If this is the case, screening for subclinical CAD in older athletes may be justified, and various different methodologies have been proposed...
January 8, 2018: Portuguese Journal of Cardiology: An Official Journal of the Portuguese Society of Cardiology
https://www.readbyqxmd.com/read/29325730/use-of-cardiovascular-polypills-for-the-secondary-prevention-of-cerebrovascular-disease
#8
J Masjuan, J Gállego, J M Aguilera, J F Arenillas, M Castellanos, F Díaz, J C Portilla, F Purroy
INTRODUCTION: There is little control of cardiovascular (CV) risk factors in secondary prevention after an ischaemic stroke, in part due to a lack of adherence to treatment. The CV polypill may contribute to proper treatment adherence, which is necessary for CV disease prevention. This study aimed to establish how and in what cases the CV polypill should be administered. METHODS: A group of 8 neurologists drafted consensus recommendations using structured brainstorming and based on their experience and a literature review...
January 8, 2018: Neurología: Publicación Oficial de la Sociedad Española de Neurología
https://www.readbyqxmd.com/read/29320517/explaining-the-decline-in-coronary-heart-disease-mortality-rates-in-the-slovak-republic-between-1993-2008
#9
Marek Psota, Piotr Bandosz, Eva Gonçalvesová, Mária Avdičová, Mária Bucek Pšenková, Martin Studenčan, Jarmila Pekarčíková, Simon Capewell, Martin O'Flaherty
OBJECTIVE: Between the years 1993 and 2008, mortality rates from coronary heart disease (CHD) in the Slovak Republic have decreased by almost one quarter. However, this was a smaller decline than in neighbouring countries. The aim of this modelling study was therefore to quantify the contributions of risk factor changes and the use of evidence-based medical therapies to the CHD mortality decline between 1993 and 2008. METHODS: We identified, obtained and scrutinised the data required for the model...
2018: PloS One
https://www.readbyqxmd.com/read/29318962/is-statin-therapy-safe-and-effective-in-patients-with-chronic-kidney-disease
#10
Venkatesh K Raman, Eleni Geladari, Vasilios Papademetriou
Chronic kidney disease (CKD) is associated with dyslipidemia and increased cardiovascular risk. This elevated risk for cardiovascular events exists even in the largest subpopulation with milder stages of CKD, prior to the development of significant reductions in renal excretory function. Statin therapy is a critical component of primary and secondary cardiovascular prevention efforts for at-risk patients. Efficacy in the CKD population, however, has appeared less robust across the spectrum of CKD, particularly in hemodialysis patients...
January 9, 2018: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/29310996/appropriateness-of-statin-prescription-in-the-elderly
#11
M Ruscica, C Macchi, C Pavanello, A Corsini, A Sahebkar, C R Sirtori
Statins, the most widely used drugs in the Western world, have become a pivotal component in the primary and secondary prevention of vascular diseases. Although benefits have been well documented in younger-than-75-year-old individuals, the value of statins in people aged >75years and over is controversial. The CTT meta-analysis calculated an absolute risk reduction of 0.6%/year per 38.7mg/dl reduction in LDL-C levels in patients aged >75years, that would translate into a number needed to treat of 167...
January 5, 2018: European Journal of Internal Medicine
https://www.readbyqxmd.com/read/29302468/the-euroaspire-surveys-lessons-learned-in-cardiovascular-disease-prevention
#12
Kornelia Kotseva
The Joint European Societies (JES) guidelines on cardiovascular disease (CVD) prevention published in 1994, 1998, 2003, 2007, 2012 and 2016 defined lifestyle and risk factors targets for patients with coronary or other atherosclerotic disease and people at high risk of developing CVD. Guideline implementation in Europe has been evaluated with four cross-sectional EUROASPIRE surveys starting in mid-1990s. The results showed poor lifestyle and risk factor management in patients with CHD and in high CVD risk people with high prevalences of smoking, obesity, central obesity and diabetes...
December 2017: Cardiovascular Diagnosis and Therapy
https://www.readbyqxmd.com/read/29299849/lipid-management-in-chronic-kidney-disease-systematic-review-of-pcsk9-targeting
#13
REVIEW
BinBin Zheng-Lin, Alberto Ortiz
Cardiovascular disease is the leading cause of death in patients with chronic kidney disease (CKD) and CKD is considered a coronary artery disease risk equivalent. So far, statins have been the mainstay of primary and secondary prevention of cardiovascular disease in the general population. However, their benefit on outcomes is limited and controversial in CKD patients and new therapeutic approaches to reduce cardiovascular risk are needed. Monoclonal antibodies targeting proprotein convertase subtilisin/kexin 9 (PCSK9) reduce low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) in high-risk populations and cardiovascular events in secondary prevention...
January 3, 2018: Drugs
https://www.readbyqxmd.com/read/29295849/central-and-brachial-blood-pressures-statins-and-low-density-lipoprotein-cholesterol-a-mediation-analysis
#14
Florence Lamarche, Mohsen Agharazii, Annie-Claire Nadeau-Fredette, François Madore, Rémi Goupil
Central blood pressure may be a better predictor of cardiovascular disease than brachial pressure. Although statins reduce brachial pressure, their impact on central pressure remains unknown. Furthermore, whether this effect is mediated through a decrease in low-density lipoprotein cholesterol (LDL-c) is unknown. This study aims to characterize the association of statins and LDL-c with central and brachial blood pressures and to quantify their respective effects. Of the 20 004 CARTaGENE participants, 16 507 had available central blood pressure, LDL-c, and Framingham risk score...
January 2, 2018: Hypertension
https://www.readbyqxmd.com/read/29291201/sickle-cell-and-alpha-thalassemia-traits-resulting-in-non-atherosclerotic-myocardial-infarction-beyond-coincidence
#15
Lee S Nguyen, Alban Redheuil, Olivier Mangin, Joe-Elie Salem
Alpha-thalassemia trait and sickle trait are not commonly considered risk factors of ischemic heart disease. We report the case of a non-atherosclerotic silent myocardial infarction in a 46-year-old woman, carrier of the alpha-thalassemia trait (homozygous deletion of locus -3.7) combined with sickle cell trait. While the patient was included as healthy volunteer for a metabolic study, we performed cardiac magnetic resonance imagery showing a left ventricle apicolateral myocardial infarction. Coronary computed tomography angiography showed normal coronary arteries with a coronary calcium score of 0...
December 16, 2017: World Journal of Clinical Cases
https://www.readbyqxmd.com/read/29287689/present-therapeutic-role-of-cholesteryl-ester-transfer-protein-inhibitors
#16
REVIEW
Nicola Ferri, Alberto Corsini, Cesare R Sirtori, Massimiliano Ruscica
Therapeutic interventions aimed at increasing high-density lipoprotein (HDL) levels, in order to reduce the residual cardiovascular (CV) risk of optimally drug treated patients have not provided convincing results, so far. Transfer of cholesterol from extrahepatic tissues to the liver appears to be the major atheroprotective function of HDL, and an elevation of HDL levels could represent an effective strategy. Inhibition of the cholesteryl ester transfer protein (CETP), raising HDL-cholesterol (HDL-C) and apolipoprotein A-I (apoA-I) levels, reduces low-density lipoprotein-cholesterol (LDL-C) and apoB levels, thus offering a promising approach...
December 26, 2017: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/29282632/effects-of-cilostazol-and-renin-angiotensin-system-ras-blockers-on-the-renal-disease-progression-of-korean-patients-a-retrospective-cohort-study
#17
Yoojin Noh, Jimin Lee, Sooyoung Shin, Inwhee Park, Soo Kyung Bae, Euichul Oh, Sukhyang Lee
Background Decline in estimated glomerular filtration rate (eGFR) is an important surrogate marker for the assessment of renal function. Addition of a second agent to angiotensin-converting-enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) treatment may improve current therapeutic strategies aimed at suppressing renal disease progression. Objective To determine the effect of cilostazol in combination with ACEI or ARB treatment on the decline in eGFR. Setting A tertiary hospital in Korea. Method In an observational cohort study, we analyzed 5505 patients who were prescribed ACEI or ARB and cilostazol or other antiplatelet agents...
December 27, 2017: International Journal of Clinical Pharmacy
https://www.readbyqxmd.com/read/29281605/trends-in-cardiovascular-risk-profiles
#18
REVIEW
Samir Kapadia
Outcomes for patients with coronary artery disease (CAD) have improved in the past 20 years likely due to advances in clinical care such as angiotensin-converting enzyme inhibitors, antiplatelet agents, and reduced time to cardiac cauterization procedures. But how have the risk factors for CAD changed in the past 2 decades? Analysis of nearly 4,000 patients with ST-elevation myocardial infarction (STEMI) at a tertiary care center found that patients presenting with acute STEMI are younger and more obese than in the past...
December 2017: Cleveland Clinic Journal of Medicine
https://www.readbyqxmd.com/read/29280370/adherence-to-nutrition-guidelines-in-patients-with-cardiovascular-diseases-cvd-as-a-secondary-prevention
#19
Agnieszka Woźniak, Monika Krótki, Anna Anyżewska, Magdalena Górnicka, Agata Wawrzyniak
Background: The appropriate nutrition is an important component of the secondary prevention of cardiovascular diseases (CVD) Objectives: The aim of the study was to investigate if the patients with cardiovascular disease were informed of the role of appropriate nutrition in prevention or received nutrition guidelines and to assess the dietary intake compared to recommendations for patients with cardiovascular disease who received or not nutrition guidelines Material and Methods: The study was conducted among patients with cardiovascular disease (n = 127) of cardiological hospital clinic, aged 62 ± 11...
2017: Roczniki Państwowego Zakładu Higieny
https://www.readbyqxmd.com/read/29278441/diabetes-news
#20
Ann M Carracher, Payal H Marathe, Kelly L Close
The American Heart Association's 2017 Scientific Sessions took place in November 2017 in Anaheim, CA, USA. Dr Kenneth Mahaffey (Stanford University, CA, USA) discussed a subgroup analysis1 of the Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes (CANVAS) trial,2 suggesting consistent heart failure and renal benefits to the sodium/glucose cotransporter 2 (SGLT-2) inhibitor Invokana (canagliflozin) across primary and secondary prevention cohorts.
December 26, 2017: Journal of Diabetes
keyword
keyword
75867
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"